(Q21261356)

Dimensions Publication ID

Dimensions

18 August 2022

Marie Rowland

2

Marie

Rowland

1 reference

Dimensions Publication ID

Dimensions

1013505985

Creative Commons Attribution 2.0 Generic

18 August 2022

language of work or name

English

0 references

publication date

4 December 2009

9 references

13 March 2019

25 April 2019

30 June 2019

25 June 2019

6 August 2019

22 October 2019

22 October 2020

24 January 2021

27 July 2022

9 references

13 March 2019

25 April 2019

30 June 2019

25 June 2019

6 August 2019

22 October 2019

22 October 2020

24 January 2021

27 July 2022

9

0 references

issue

1

0 references

page(s)

59

0 references

copyright license

9 references

13 March 2019

25 April 2019

30 June 2019

25 June 2019

6 August 2019

22 October 2019

22 October 2020

24 January 2021

on focus list of Wikimedia project

27 July 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Treatments for spasticity and pain in multiple sclerosis: a systematic review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Endocannabinoids control spasticity in a multiple sclerosis model

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Cannabidiol: a promising drug for neurodegenerative disorders?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Cannabinoids in the management of spasticity associated with multiple sclerosis.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Cannabinoid system and neuroinflammation: implications for multiple sclerosis.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Combined cannabinoid therapy via an oromucosal spray

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Medicinal cannabis extracts for the treatment of multiple sclerosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Anti-spasticity agents for multiple sclerosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Cannabinoids in clinical practice

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

The perceived effects of smoked cannabis on patients with multiple sclerosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793241

Patterns of cannabis use among patients with multiple sclerosis

12 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2377-9-59

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2377-9-59

Delta-9-THC in the treatment of spasticity associated with multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19961570

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19961570